What are the weight‑based pediatric doses of trimethoprim‑sulfamethoxazole (trimethoprim dose and sulfamethoxazole dose calculated as five times trimethoprim) for routine infections, severe infections, intravenous administration, and PCP prophylaxis and treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pediatric Dosing of Trimethoprim-Sulfamethoxazole

For routine pediatric infections, administer 8 mg/kg/day trimethoprim with 40 mg/kg/day sulfamethoxazole divided every 12 hours; for severe infections and PCP treatment, use 15–20 mg/kg/day trimethoprim with 75–100 mg/kg/day sulfamethoxazole divided every 6 hours; for PCP prophylaxis, give 150 mg/m²/day trimethoprim with 750 mg/m²/day sulfamethoxazole divided twice daily on 3 consecutive days per week. 1

Routine Infections (UTI, Otitis Media, Shigellosis)

Oral Dosing

  • Administer 8 mg/kg trimethoprim + 40 mg/kg sulfamethoxazole per 24 hours, divided into 2 doses every 12 hours. 1
  • Duration: 10 days for UTI/otitis media, 5 days for shigellosis. 1
  • Contraindicated in infants <2 months of age. 1

Weight-Based Tablet Dosing Guide

  • 10–20 kg: 1 single-strength tablet every 12 hours 1
  • 30 kg: 1½ single-strength tablets every 12 hours 1
  • 40 kg: 2 single-strength tablets (or 1 double-strength tablet) every 12 hours 1

Severe Infections and Skin/Soft Tissue Infections

MRSA Skin Infections (Purulent Cellulitis)

  • Oral dosing: Trimethoprim 4–6 mg/kg/dose + sulfamethoxazole 20–30 mg/kg/dose every 12 hours. 2
  • This represents a moderate-intensity regimen between routine and PCP treatment dosing. 2
  • Avoid in third-trimester pregnancy and children <2 months. 2

Intravenous Administration for Complicated Infections

  • The FDA label provides oral dosing guidance but does not specify distinct IV pediatric dosing for routine infections. 1
  • For severe infections requiring IV therapy, follow PCP treatment dosing principles (see below) and adjust based on clinical severity. 1

Pneumocystis Jirovecii Pneumonia (PCP)

Treatment Dosing

  • 15–20 mg/kg/day trimethoprim + 75–100 mg/kg/day sulfamethoxazole, divided into 4 doses every 6 hours. 1
  • Duration: 14–21 days. 1
  • Both oral and IV routes achieve similar serum levels and can be used interchangeably. 3

Weight-Based Treatment Guide (Upper Limit Dosing)

  • 8–16 kg: 1 single-strength tablet every 6 hours 1
  • 24 kg: 1½ single-strength tablets every 6 hours 1
  • 32 kg: 2 single-strength tablets (or 1 double-strength) every 6 hours 1
  • 40 kg: 2½ single-strength tablets every 6 hours 1
  • 48 kg: 3 single-strength tablets (or 1½ double-strength) every 6 hours 1
  • For lower limit dosing (15 mg/kg trimethoprim), administer 75% of the above doses. 1

PCP Prophylaxis

  • 150 mg/m²/day trimethoprim + 750 mg/m²/day sulfamethoxazole, divided every 12 hours, given on 3 consecutive days per week. 1, 2
  • Maximum daily dose: 320 mg trimethoprim + 1600 mg sulfamethoxazole. 1

Body Surface Area Dosing Guide for Prophylaxis

  • 0.26–0.53 m²: ½ single-strength tablet every 12 hours (on designated days) 1
  • 1.06 m²: 1 single-strength tablet every 12 hours (on designated days) 1

Critical Dosing Considerations

Renal Impairment

  • Creatinine clearance 15–30 mL/min: Reduce dose to 50% of usual regimen. 1
  • Creatinine clearance <15 mL/min: Use not recommended. 1
  • Trimethoprim clearance inversely correlates with serum creatinine in children. 4

Pharmacokinetic Pitfalls

  • Serum levels accumulate over 4–6 days despite loading doses, with trough concentrations rising 63% for trimethoprim and 102% for sulfamethoxazole. 3
  • Large interindividual variability occurs despite weight-based dosing, particularly in high-dose regimens. 3
  • Trimethoprim clearance increases with age; younger children (<6 years) may require higher mg/kg doses to match adult exposures. 4

Safety Monitoring

  • Thrombocytopenia is the most common cause of discontinuation (37% of cases), particularly in patients ≥50 years, lymphocyte count <1000/μL, or baseline platelet count <180,000/μL. 5
  • Monitor complete blood counts regularly, especially during prolonged therapy. 5
  • Transient neutropenia may occur but often resolves spontaneously. 6

Age-Specific Warnings

  • Absolutely contraindicated in infants <2 months of age due to risk of kernicterus from sulfamethoxazole displacement of bilirubin. 1
  • Tetracyclines (alternative MRSA agents) are contraindicated in children <8 years, making TMP-SMX a preferred oral option for this age group. 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.